Repurposing compounds for the treatment of infections and for modulating the composition of the gut microbiome

US11766427B2 · kind B2 · utility

Assignee

• European Molecular Biology Laboratory · DE

Inventors

• MIHAELA PRUTEANU · Berlin, DE
• LISA MAIER · Boston, US
• Michael Kuhn · Bochum, DE
• Peer Bork · Heidelberg, DE
• ATHANASIOS TYPAS · Heidelberg, DE
• Kiran Raosaheb Patil · Cambridge, GB
• GEORG ZELLER · Heidelberg, DE

Key dates

• Filing date: Feb 13, 2019
• Grant date: Sep 26, 2023
• Expiry date: Jul 29, 2039

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to agents and compositions for the modification of the growth of bacterial cells. Thus, the compounds of the present invention are useful for the prevention and/or treatment of a disease in a subject. In particular, the present invention relates to the field of repurposing pharmaceutical compounds for treatment strategies of infectious diseases, gastrointestinal disorders, inflammatory diseases, proliferative diseases, metabolic disorders, cardiovascular diseases, and immunological diseases. Some of the compounds of the present invention demonstrate high specificity in inhibiting the growth of single bacterial species. Such compounds enable narrow-spectrum antibacterial therapies, constituting a major effort of current and future drug development strategies in order to reduce side effects of antibacterial treatment plans. Particularly interesting compounds of this invention are effective against pathobiological species such as Clostridium difficile, Clostridium perfingens, Fusobacterium nucleatum, and an enterotoxigenic strain of Bacteroides fragilis. Other compounds of the present invention reveal a strong inhibitory effect on a broad spectrum of bact…